US9842411095 - Common Stock
Y-MABS THERAPEUTICS INC
NASDAQ:YMAB (5/17/2024, 7:00:03 PM)
After market: 11.6 0 (0%)11.6
-0.25 (-2.11%)
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 147 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS (omburtamab), which targets tumors that express B7-H3. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb) that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. Omburtamab is a novel murine monoclonal antibody designed for compartmental immunotherapy. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several types of cancers, including pediatric CNS/LM from NB.
Y-MABS THERAPEUTICS INC
230 Park Avenue, Suite 3350
New York City NEW YORK 10169
P: 12128479841
CEO: Claus Juan Moller San Pedro
Employees: 147
Website: https://www.ymabs.com/
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Y-mAbs Therapeutics (NASDAQ:YMAB) just reported results for the first quarter o...
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET...
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Here you can normally see the latest stock twits on YMAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: